# Trade Mark Journal No.2026/011 13 March 2026

## UK00004345395 25 February 2026 (5,40,42)

CALLIO THERAPEUTICS

International priority date claimed: 26 August 2025 (United States of America) (99357977)

Class 5
  Pharmaceutical and biological preparations for treating cancer; Pharmaceuticals and biological preparations for prophylactic, diagnostic, and therapeutic use in treating, preventing, and managing cancer; Therapeutic agents for medical use, namely, proteins and derivatives, antibody-drug conjugates, immunostimulatory antibody-drug conjugates, antibodies with multiple drug or cytokine conjugates, multispecific antibodies, and engineered antibodies for treating cancer; Pharmaceutical and biological preparations for the prevention, diagnosis and treatment of cancer for clinical, medicinal, therapeutic and diagnostic purposes; Pharmaceutical and biological preparations for use in oncology for treating cancer.
Class 40
  Custom manufacturing of pharmaceuticals and therapeutic agents for medical use.
Class 42
  Research and development in the fields of pharmaceuticals, biologics, chemistry, protein engineering, proteins and derivatives, antibody-drug conjugates, immunostimulatory antibody-drug conjugates, antibodies with multiple drug or cytokine conjugates, multispecific antibodies, and engineered antibodies, oncology; Providing medical scientific research information in the fields of pharmaceuticals, biologics, chemistry, protein engineering, proteins and derivatives, antibody-drug conjugates, immunostimulatory anti-drug conjugates, antibodies with multiple drug or cytokine conjugates, multispecific antibodies, and engineered antibodies, oncology, and immunology; Drug discovery, custom design, and development services featuring therapeutic agents for the treatment and prevention of diseases; Scientific investigations for medical purposes; Scientific research in the nature of conducting clinical trials for others.

Callio Operating Co, Inc.

Representative: Mewburn Ellis LLP